However, results from a phase I clinical study [38] testing the safety of NKG2D CAR-T cells in patients with AML/MDS and multiple myeloma (ClinicalTrials.gov Identifier: NCT03018405) are promising with no reported cases of cytokine-release syndrome, CAR T cell-related neurotoxicity, autoimmunity, or patient death. This evidence concerns the gene KLRK1 and Autoimmunity.